More U.S. adults are dying from heart failure today than a decade ago, and the sharpest rise in mortality is happening among middle-aged and younger adults, a new study suggests.

Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

With increased access to insurance under the Affordable Care Act (also known as Obamacare), fewer uninsured patients have been hospitalized for serious heart conditions, a U.S. study suggests.

Bayer and Johnson & Johnson’s campaign to widen the patient group for the companies’ heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.

Pfizer Inc. announced that tafamidis received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with transthyretin cardiomyopathy, which is a rare, fatal and underdiagnosed condition associated with progressive heart failure.

A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.

Eiger BioPharmaceuticals Inc. will stop development of a drug to treat pulmonary arterial hypertension after it failed in a mid-stage study.

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.